Steglatro Tablets 5 Milligrams (Ertugliflozin L-Pyroglutamic Acid)
Ertugliflozin L-Pyroglutamic Acid 6.477mg
Tablet · Prescription medication
Korea MSD Co., Ltd.
MFDS item code 201803367 · Approved 2018.08.17
This product's status changed to Approval revoked on 2025.10.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help control blood sugar in adult patients with type 2 diabetes. It can be used alone or in combination with other medications. Particularly, for patients with poor blood sugar management who have cardiovascular disease, it is essential to verify the precautions related to the occurrence of cardiovascular events. This medication effectively controls blood sugar levels and helps improve diabetes management.
The recommended starting dose of this medicine is 5 mg once daily, both as monotherapy and in combination with other antihyperglycemic agents such as metformin. Take this medicine orally once daily in the morning, with or without food. If 5 mg is well tolerated and additional glycemic control is needed, the dose may be increased to 15 mg once daily. In patients with volume depletion, correct the volume status before administering this medicine. [See Precautions for Use, 2. Patients Requiring Caution, 1) Volume Depletion, and 3. Adverse Reactions, 2) Specific Adverse Reactions, ① Volume Depletion.] When this medicine is used concomitantly with a sulfonylurea or insulin, dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia [see Precautions for Use, 3. Adverse Reactions, 2) Specific Adverse Reactions, ⑤ Hypoglycemia.] Special populations • Patients with renal impairment The efficacy of this medicine depends on renal function. Assess renal function before starting treatment and periodically during treatment [see Precautions for Use, 2. Patients Requiring Caution, 1) Volume Depletion]. Use of this medicine to improve glycemic control is not recommended in patients with an estimated glomerular filtration rate (eGFR) < 45mL/min/1.73 m2. Discontinue this medicine if eGFR is persistently < 30mL/min/1.73 m2. • Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. • Elderly patients Dose adjustment of this medicine based on age is not recommended. Consider the risk of volume depletion. Initiation of treatment is not recommended in patients aged 75 years or older because experience in this age group is limited [see Precautions for Use, 8. Use in Elderly Patients].
This medication should not be administered to certain patients. First, it is not used in patients who have had severe allergic reactions to the main ingredient or excipients of this drug, type 1 diabetes patients, patients with diabetic ketoacidosis, patients with significantly impaired kidney function or those undergoing dialysis. Additionally, this medication contains lactose, so patients with genetic conditions such as lactose intolerance or galactose intolerance should not take it. Patients at risk of reduced blood volume or low blood pressure should use this medication with caution. In particular, patients with poor kidney function, elderly patients, and those taking diuretics should carefully monitor their blood status before treatment and closely observe during treatment as they may experience blood volume reduction and hypotension. In cases of severe congestive heart failure, the use of this medication is not recommended. This medication can cause a serious metabolic disorder known as ketoacidosis, so if symptoms such as vomiting, abdominal pain, or difficulty breathing occur, consult a doctor immediately. There may be a tendency for fungal infections to occur in the genital area, so it's important to seek treatment if there are signs of infection. While taking this medication, side effects such as headaches, urinary tract infections, vulvar itching, increased urination, and thirst may occur, so it's important to be aware of these symptoms. Regular kidney function tests are necessary to ensure that there are no abnormalities. Additionally, this medication may increase the risk of hypoglycemia, requiring careful monitoring of blood sugar levels. Women who are pregnant or breastfeeding should not use this medication and should stop taking it immediately if pregnancy is confirmed. The safety of this medication in children and adolescents has not been established, so it is advisable not to use it. Elderly patients should take caution as they may experience side effects related to reduced blood volume more frequently. Patients with severe impairment of kidney or liver function should not use this medication or should use it cautiously. In the event of an overdose, appropriate treatment should be given according to the symptoms, and it is not clear whether this medication can be removed by dialysis. Finally, this medication should be stored out of reach of children, not transferred to other containers, and handled safely.
Genital fungal infection, urinary tract infection, headache, vulvar pruritus, increased urination, nasopharyngitis, back pain, weight loss, thirst, dehydration, orthostatic dizziness, pre-syncope, syncope, hypotension, orthostatic hypotension, ketoacidosis, increased serum creatinine, decreased eGFR, lower limb amputation, hypoglycemia, phimosis, rash, necrotizing fasciitis of the perineum (Fournier's gangrene)
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius.
Pink, bilaterally convex, triangular film-coated tablet with '701' engraved on one side.
28 tablets
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ertugliflozin L-Pyroglutamic Acid 6.477mg
Tablet · Prescription medication
Korea MSD Co., Ltd.
Ertugliflozin L-Pyroglutamic Acid
Prescription medication
Korea MSD Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.